I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

Two of President Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.

Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...